Results 71 to 80 of about 51,507 (268)

Metastatic Cutaneous Adnexal Carcinoma of the Head and Neck With Durable Response to an Aromatase Inhibitor Combined With a Cyclin‐Dependent Kinase 4/6 Inhibitor

Head &Neck, EarlyView.
ABSTRACT Background Cutaneous adnexal carcinomas are a very rare group of cancers arising from appendageal structures of the skin. More than half occur in the head and neck region. No standard treatments exist for metastatic disease. Methods A 48‐year‐old postmenopausal female presented with an enlarging scalp lesion.
Nilesh Kapoor, Manasa Narasimman, Travis Vandergriff, Amy L. Jones   +3 more
wiley   +1 more source

Manejo farmacológico da baixa estatura: o papel dos inibidores da aromatase Pharmacological management of children with short stature: the role of aromatase inhibitors

Jornal de Pediatria, 2007
OBJETIVO: Revisão sobre o uso de inibidores de aromatase, uma nova modalidade terapêutica em pacientes com baixa estatura, numa tentativa de evitar o avanço rápido da idade óssea, dependente da produção estrogênica, mesmo no sexo masculino.
Durval Damiani, Daniel Damiani
doaj   +1 more source

A qualitative comparison of how older breast cancer survivors process treatment information regarding endocrine therapy. [PDF]

, 2019
BACKGROUND:It remains unclear how information about aromatase inhibitors (AI) impacts women's decision-making about persistence with endocrine therapy.
Green, Emily, Khakshooy, Sally, Pieters, Huibrie C, Sleven, Miriam, Stanton, Annette L   +4 more
core   +4 more sources

Sequencing of aromatase inhibitors [PDF]

British Journal of Cancer, 2005
Since the development of the third-generation aromatase inhibitors (AIs), anastrozole, letrozole and exemestane, these agents have been the subject of intensive research to determine their optimal use in advanced breast cancer. Not only have they replaced progestins in second-line therapy and challenged the role of tamoxifen in first-line, but there is
openaire   +2 more sources

Long‐term benefit from adjuvant tamoxifen therapy for ER+ HER2− breast cancer by PR positivity

International Journal of Cancer, EarlyView.
What's New? Tamoxifen is a cornerstone of endocrine therapy for estrogen receptor (ER)‐positive/human epidermal growth factor receptor 2 (HER2)‐negative breast cancer. Its long‐term benefits, however, may vary by progesterone receptor (PR) status. Here, using data from the Stockholm tamoxifen trials, the authors evaluated whether PR expression predicts
Anna E. Nordenskjöld, Magdalena Ríos‐Romero, Huma Dar, Tommy Fornander, Gizeh Perez‐Tenorio, Helena Fohlin, Olle Stål, Julia Tutzauer, Linda S. Lindström   +8 more
wiley   +1 more source

Impact of aromatase inhibitors on thyroid function in postmenopausal women with early-stage breast cancer: a prospective controlled study

Cancer Treatment and Research Communications
Purpose: Aromatase inhibitors are commonly used in adjuvant therapy for breast cancer. However, their impact on thyroid function remains unclear. This study aimed to evaluate thyroid function in postmenopausal women with oestrogen-receptor-positive early-
Djordje Marina, August Nielsen, Kristian Buch-Larsen, Michael Andersson, Åse Krogh Rasmussen, Peter Schwarz   +5 more
doaj   +1 more source

The relationship between oestrogen receptor-alpha phosphorylation and the tumour microenvironment in patients with primary operable ductal breast cancer [PDF]

, 2017
Aims: Although the role of phosphorylation of oestrogen receptor (ER) at serines 118 (p-S118) and 167 (p-S167) has been studied, the relationship between p-S118, p-S167 and the tumour microenvironment in ER-positive primary operable ductal breast ...
Arnold, Bartlett, Brouckaert, Ciucci, Fan, Faratian, Gilchrist, Gujam, Gujam, Harvey, Jiang, Kirkegaard, Klintrup, Kok, Lannigan, Li, McCarty, Medrek, Mohammed, Mohammed, Mohammed, Mohammed, Mohammed, Mohammed, Mouridsen, Paik, Ring, Roxburgh, Salhia, Sarwar, Srinivas, Svensson, Toy, Ueno, Uzzan, Vassilakopoulou, Weitsman, Yamashita, Yamashita   +38 more
core   +1 more source

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, EarlyView.
What's New? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

Nelumal A, the Active Principle of , is a Novel Aromatase Inhibitor

Natural Product Communications, 2014
Nelumal A, the active principle of Ligularia nelumbifolia was preliminarily tested as an aromatase inhibitors in HEK293 cells transfected with aromatase cDNA and using anastrazole as the reference drug.
Francesco Epifano, Salvatore Genovese, Serena Fiorito, Chantal Magne Nde, Colin Clyne   +4 more
doaj   +1 more source

Molecular Docking of Aromatase Inhibitors

Molecules, 2011
Aromatase is an enzyme that plays a critical role in the development of estrogen receptor positive breast cancer. As aromatase catalyzes the aromatization of androstenedione to estrone, a naturally occurring estrogen, it is a promising drug target for ...
Virapong Prachayasittikul, Naravut Suvannang, Chanin Nantasenamat, Chartchalerm Isarankura-Na-Ayudhya   +3 more
doaj   +1 more source